Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 14/20 | 0.78 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12990046 | 0.96 | SIRT1 (0.77) | SIRT1SIRT2RECQLSIRT3GAA | |
| SCHEMBL15451340 | 0.88 | SIRT1 (1.00) | SIRT1SIRT2RECQLSIRT3GAA | |
| SCHEMBL15445321 | 0.85 | SIRT1 (0.57) | SIRT1SIRT2RECQLSIRT3MAPT | |
| SCHEMBL12988711 | 0.85 | SIRT1 (0.78) | SIRT1SIRT2RECQLSIRT3MAPT | |
| SCHEMBL8244015 | 0.84 | SIRT1 (1.00) | SIRT1SIRT2RECQLSIRT3GAA | |
| SCHEMBL29915361 | 0.84 | SIRT1 (1.00) | SIRT1SIRT2RECQLSIRT3GAA | |
| SCHEMBL12989489 | 0.81 | SIRT1 (0.77) | SIRT1SIRT2RECQLSIRT3MAPT | |
| SCHEMBL12989592 | 0.81 | SIRT1 (0.57) | SIRT1SIRT2RECQLSIRT3MAPT | |
| SCHEMBL1872225 | 0.80 | SIRT1 (1.00) | SIRT1SIRT2RECQLSIRT3GAA | |
| SCHEMBL16266029 | 0.78 | SIRT1 (0.85) | SIRT1SIRT2RECQLSIRT3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | SIRT1 1/4885SIRT2 2/4885RECQL 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.